EFA vs IBB
iShares MSCI EAFE ETF vs iShares Biotechnology ETF
- • EFA has the lower expense ratio at 0.32% vs 0.44% for IBB.
- • EFA pays a higher dividend yield (3.24%).
Side-by-side metrics
| Metric | EFA | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.32% | 0.44% |
Dividend yield Trailing 12-month yield. | 3.24% | 0.22% |
AUM Assets under management — bigger funds are typically more liquid. | $77.22B | $9.09B |
YTD return | 9.33% | 16.44% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.87 | 0.69 |
P/E ratio | 18.89 | 24.79 |
Last price | $104.16 | $196.62 |
Inception | — | — |
Issuer | iShares | iShares |
EFA top holdings
| ASML.AS | ASML Holding NV | 3.52% |
| HSBA.L | HSBC Holdings PLC | 1.50% |
| ROP.SW | Roche Holding AG Ordinary Shares new | 1.34% |
| NOVN.SW | Novartis AG Registered Shares | 1.32% |
| AZN.L | AstraZeneca PLC | 1.31% |
| NESN.SW | Nestle SA | 1.22% |
| SIE.DE | Siemens AG | 1.10% |
| SHEL.L | Shell PLC | 1.01% |
| 8035.T | Tokyo Electron Ltd | 0.98% |
| 8306.T | Mitsubishi UFJ Financial Group Inc | 0.97% |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
About EFA
EFA (iShares MSCI EAFE ETF) is Developed-market equities outside US/Canada. Managed by iShares, the fund carries $77.2B in assets under management, an expense ratio of 0.32%, a dividend yield of 3.24%. Its largest holding is ASML Holding NV (ASML.AS), which represents 3.5% of the portfolio. Real Estate is the fund's largest sector exposure at 1.7%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.